Chemotherapy
Malignant Pleural Mesothelioma: Staging and Radiological Response Criteria in Patients Treated with Immune Checkpoint Inhibitors
Targeted Oncology 2023 December 8 [Link] Serafina Martella, Marco Maria Aiello, Valentina Bertaglia, Riccardo Cau, Nerina Denaro, Andrea Cadoni, Silvia Novello, Mario Scartozzi, Giuseppe Novello, Hector Josè Soto Parra, Luca Saba, Cinzia Solinas, Michele Porcu Abstract Malignant pleural mesothelioma (MPM) is a rare and challenging cancer associated with asbestos fiber exposure, which offers limited treatment…
Read MoreCase Report: Early diagnosis and bevacizumab-based chemotherapy for primary pericardial mesothelioma: a case with occupational asbestos exposure history
Frontiers in Cardiovascular Medicine 2023 November 20 [Link] Daniel Wang, Yung Hsuan Wang, Sung Chao Chu Abstract Background: Primary pericardial mesothelioma (PPM) is an exceedingly rare malignant cancer and has a poor prognosis, which has been partly attributed to its frequently delayed diagnosis due to its nonspecific syndromes, its similar presentation to benign pericardial diseases,…
Read MoreRandomized trial of intravenous versus bidirectional chemotherapy after cytoreductive surgery for malignant peritoneal mesothelioma
International Journal of Surgical Protocols 2023 September 26 [Link] Paul H Sugarbaker Abstract Background: Malignant peritoneal mesothelioma (MPM) is a rare disease that progresses within the peritoneal cavity and only disseminates to systemic sites in the terminal months of the disease. For this malignancy, there are several regimens of chemotherapy that have been accepted as…
Read MoreA deep learning-based model (DeepMPM) to help predict survival in patients with malignant pleural mesothelioma
Translational Cancer Research 2023 October 31 [Link] Wei Li, Minghang Zhang, Siyu Cai, Siqi Li, Biao Yang, Shijie Zhou, Yuanming Pan, Shaofa Xu Abstract Background: Malignant pleural mesothelioma (MPM) is a rare disease with limited treatment and poor prognosis, and a precise and reliable means to predicting MPM remains lacking for clinical use. Methods: In…
Read MoreCrosstalk with lung fibroblasts shapes the growth and therapeutic response of mesothelioma cells
Cell Death and Disease 2023 November 8 [Link] Yakinthi Chrisochoidou, Rajat Roy, Pooyeh Farahmand, Guadalupe Gonzalez, Jennifer Doig, Lukas Krasny, Ella F Rimmer, Anne E Willis, Marion MacFarlane, Paul H Huang, Neil O Carragher, Alison F Munro, Daniel J Murphy, Kirill Veselkov, Michael J Seckl, Miriam F Moffatt, William O C Cookson, Olivier E Pardo…
Read MoreImpact of Perioperative Systemic Chemotherapy on Survival for Patients Who have Diffuse Malignant Peritoneal Mesothelioma Treated with CRS-HIPEC
Annals of Surgical Oncology 2023 January [Link] Ambarish Chatterjee, Shigeki Kusamura, Dario Baratti, Marcello Guaglio, Luigi Battaglia, Marcello Deraco Abstract Background: The available data on the role of perioperative systemic chemotherapy (SC) for diffuse malignant peritoneal mesothelioma (DMPM) patients undergoing (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is heterogeneous and unstandardized. This study aimed to evaluate…
Read MoreCo-existing pericardial and pleural malignant mesothelioma responding well to nedaplatin and pemetrexed: a case report
AME Case Reports 2023 August 3 [Link] Mindan Wu, Zhixuan Li, Junfu Cai, Xianyang Zhong, Wenchuan Zheng, Shuhan Wu, Maohuang Lin, Qichuan Zhang Abstract Background: Malignant mesothelioma (MM) is a rare cancer with poor prognosis. It is less common that two serosal cavities are involved when the patient seeks medical attention firstly. The current first-line…
Read MorePleural mesothelioma: a snapshot of emerging drug targets and opportunities for non-surgical therapeutic advancement
Expert Opinion on Therapeutic Targets 2023 October 30 [Link] Jean-Baptiste Assié, Didier Jean Abstract Introduction: Pleural mesothelioma is a rare and aggressive cancer originating in the pleura, with a devastating prognosis and limited treatment options. There have been significant advancements in the management of this disease in recent years. Since 2021, nivolumab and ipilimumab immune…
Read MoreThe prognostic value of F18 Fluorothymidine positron emission tomography for assessing the response of malignant pleural mesothelioma to chemotherapy – A prospective cohort study
Journal of Medical Imaging and Radiation Oncology 2023 October 29 [Link] Isaac J May, Anna K Nowak, Roslyn J Francis, Martin A Ebert, Satvinder S Dhaliwal Abstract Introduction: Malignant pleural mesothelioma is difficult to prognosticate. F18-Fluorodeoxyglucose positron emission tomography (FDG PET) shows promise for response assessment but is confounded by talc pleurodesis. F18-Fluorothymidine (FLT) PET…
Read MorePerioperative discordance in mesothelioma cell type after pleurectomy/decortication-a possible detrimental effect of neoadjuvant chemotherapy due to epithelial to mesenchymal transition?
Interdisciplinary Cardiovascular Thoracic Surgery 2023 November 2 [Link] Luigi Ventura, Michelle Lee, Ralitsa Baranowski, Joanne Hargrave, Michael Sheaff, David Waller Abstract Objectives: The goal was to evaluate the accuracy of preoperative histological assessment and the factors affecting the accuracy and the subsequent effect on postoperative survival after surgical treatment for malignant pleural mesothelioma (MPM). Methods:…
Read More